Compare · ANGO vs RMD
ANGO vs RMD
Side-by-side comparison of AngioDynamics Inc. (ANGO) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANGO and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $31.73B, about 48.5x ANGO ($653.9M).
- Over the past year, ANGO is up 79.1% and RMD is down 23.1% - ANGO leads by 102.1 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 2 for ANGO).
- RMD has more recent analyst coverage (25 ratings vs 8 for ANGO).
- Company
- AngioDynamics Inc.
- ResMed Inc.
- Price
- $15.83+1.09%
- $219.99-0.15%
- Market cap
- $653.9M
- $31.73B
- 1M return
- +15.42%
- +10.75%
- 1Y return
- +79.07%
- -23.06%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 2
- 7
- Recent ratings
- 8
- 25
AngioDynamics Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ANGO
- SVP Quality and Regulatory Nighan Warren Jr sold $344,006 worth of shares (23,370 units at $14.72), decreasing direct ownership by 27% to 64,745 units (SEC Form 4)
- AngioDynamics to Participate in Upcoming Investor Conferences
- SVP International Piccinini Laura converted options into 8,047 shares and covered exercise/tax liability with 4,506 shares, increasing direct ownership by 5% to 81,929 units (SEC Form 4) (tax withholding)
- EVP and CFO Trowbridge Stephen A converted options into 16,296 shares and covered exercise/tax liability with 8,319 shares, increasing direct ownership by 3% to 305,796 units (SEC Form 4) (tax withholding)
- President and CEO Clemmer James C converted options into 52,358 shares and covered exercise/tax liability with 26,728 shares, increasing direct ownership by 3% to 862,448 units (SEC Form 4) (for withholding tax)
- SVP Quality and Regulatory Nighan Warren Jr converted options into 5,694 shares and covered exercise/tax liability with 1,671 shares, increasing direct ownership by 5% to 88,115 units (SEC Form 4) to satisfy withholding obligation
- SVP/GM, Vascular Access Campbell Chad Thomas converted options into 6,466 shares and covered exercise/tax liability with 2,330 shares, increasing direct ownership by 4% to 108,676 units (SEC Form 4) to satisfy withholding obligation
- Director Johnson Wesley was granted 11,887 shares, increasing direct ownership by 8% to 155,425 units (SEC Form 4)
- SVP Quality and Regulatory Nighan Warren Jr was granted 17,966 shares, increasing direct ownership by 27% to 84,092 units (SEC Form 4)
- Director Burgess Lorinda was granted 11,887 shares, increasing direct ownership by 22% to 67,144 units (SEC Form 4)
Latest RMD
- SEC Form 8-K filed by ResMed Inc.
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- SEC Form 10-K filed by ResMed Inc.
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,026,596 worth of ResMed Common Stock (4,991 units at $205.69) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
- Director Farrell Peter C sold $1,800,000 worth of ResMed Common Stock (8,000 units at $225.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 52,773 units (SEC Form 4)
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target